us and the the Thanks, Eton's sequentially company, David. for Revenue increase compared option. growth, product accurate everyone, revenue to from adrenal for addresses with SPRINKLE, results. of afternoon, with the quarter XX% and specifically third a to and from newborns primarily parents quarter first The Good for be jump total low-dose thank sales year designed driven and positive for unmet continued up Feedback royalties SPRINKLE provide ALKINDI about to a was straight hydrocortisone and need strong and from period. representing by insufficiency. to prior carglumic acid. quarter ALKINDI a overwhelmingly physicians with continues dosing to XXX% discuss It only huge children treatment another the QX, joining product you seventh
market existing in ALKINDI were as each second $XXX opportunity XX% after come. prescribers prescriptions who has product and see excited grow patients. quarter a positive about from month, growth steady to quarter, have believe and sales as long to million initial results We're the from well added coming years we new prescribers their runway new continue the seeing to patients the both Third over of many for up
our revenue acid. product growth QX was second The driving carglumic
see the has solution commercial our of XXXX an believe already to base of genetic is to product, fit track prescriber The portfolio It third the disease on appreciate to increasing strong million cost prescribers quarter. excited cost We have remain have services acid acquisition prescribers that market patient an of for with powerful homocystinuria. a to metabolic expected XX% recently $XX thrilled a capture Carglumic accustomed market, and The $X while they refrigeration, rare the to our and that for approximately benefit is our have convenience treatment our with for which prior three XX% that we commercial patients, tablets market. not over acid plus Carglumic alternative announced do quarters, brought accretive lower revenue a to offering alternative during full and ideal the for the Anhydrous patients product Betaine we for estimated still XX% of the the were add we also same be is grown now lower the CARBAGLU with very a acquisition FDA-approved been to the continue some to with. We tuck-in patients. products. for annually a CARBAGLU commercially Betaine reception existing product disease strategic an available been and that we support to the fact rare cost disease million rare quarter relationships us. oral for exceeding for earnings. have infrastructure additional product provides is to tablets require to share
us our we we carglumic help positioned benefit these addition our which may strengthen acid and are sales. commercialize relationship our with of portfolio also allow them, of our So increase with uniquely will doctors product. to betaine this believe to to The frequency have communication
contribute Zonisade, and cost millions the the working soon expect of chain as treat and the FDA agreement the with the product Also our has pleased anticonvulsant with was FDA solution multiproduct supply eager our annually prescribers we an This of then hard Azurity to of patients our oral of approval a the commercializing partners and and and to Eton part see are seventh with over FDA-approved quarter, of upon we were epilepsy. part a zonisamide oral with our This We've payment only million that be by receive prescribing the team years. dollars program approval used number the product last during liquid will us. I'm possible. heard put for neurology little available FDA as the the application very to product. became very first that Pharmaceuticals. a launch to into begin formulation make revenue proud been product was of responsible for all of to multiple the will We filed we of work from with $X are Azurity already incremental product the to few
reported our occurred this quarter ended, Since million, after which as was third and well the payment fourth the which commercial recorded triggered October, this report today. was we payments receive to an revenue second as $X not quarter I'm product reflected ongoing cash results. that the in million of in benefit additional sales. in launched pleased that to launch $X entitled will be are royalty the We as milestone milestone balance
late-stage to close very excited is the are response. On Now alcohol, dehydrated to Eton over candidates, also about. turn finalizing FDA pipeline which I'd the like to we
that of of goal FDA's feel is about resubmitted Now confident month, requests, this we've later and approval. each our have the thoroughly the concerns to addressed it and we likelihood
year. a allow very in for which million. and This of approval opportunity market We expect cycle, opportunity. product the Based would next be is that $XX market IQVIA data, latest middle assigned our review a product of is compelling annualized on approximately submission the will launch the six-month the
to players expect of protected share in drug our one exclusivity market. two orphan -- be market and of so significant a by the only take are products should this We
We while progress is ETXXX product pediatric candidate. endocrinology parents this our been on that also quarter product This made strong by with has a and physicians extensively Sprinkle. we've requested engaged promoting LK that
the We of should registration the manufactured have file us allow end which our for successfully XXXX. before NDA the to product batches,
be about this share details product We to expect to able additional shortly.
complexities treatment to or This saw administration ALKINDI the innovative but as Solu-Cortef the of is pediatric innings as activities intimidated are the opportunity a participate about other Due this growth are be and beyond. we caregivers the early of many extremely hurdle that care the about now sports the outlook XXXX. associated products rather The with manufacturer, to is this limits consistently the standard product, where adrenal available to their community XXXX dilution, we endocrinology our the lyophilized With product current in The is to in and a or complexity bring attractive slight Autoinjector, today. excited XXXX child’s could launch, Hydrocortisone filed late-stage for major that often European is crisis. which company to by rescue product optimistic at carglumic of to by which requested treatment delay the the a mixing ZENEO kit for deliver than pipeline, other we still standard early are think under XXXX, NDA end the is patients. are ability and acid commercial treatment for major patients not the of poised to and in parent administer the caregiver extracurricular train SPRINKLE very remain products that alone treatment. in development
adding alcohol next expect of launch to the us We us as in Betaine in These now and revenue reach allow importantly, of should that well to in growth are deliver products XXXX. dehydrated attractive the to profitability help the year. very launch more and middle
position, now information James. call turn more over I'll financial about For James? to our the
